Merck & Co., Inc. (LON:MRK)

London flag London · Delayed Price · Currency is GBP · Price in GBX
59.11
-1.39 (-2.30%)
Sep 15, 2025, 11:40 AM BST
-2.30%
Market Cap152.63B
Revenue (ttm)46.43B
Net Income (ttm)11.97B
Shares Outn/a
EPS (ttm)4.73
PE Ratio12.75
Forward PE9.00
Dividendn/a
Ex-Dividend Daten/a
Volume2,764
Average Volume19,567
Open59.11
Previous Close60.50
Day's Range59.11 - 59.11
52-Week Range48.00 - 65.00
Beta0.68
RSI34.22
Earnings DateOct 30, 2025

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu... [Read more]

Founded 1891
Employees 75,000
Stock Exchange London Stock Exchange
Ticker Symbol MRK
Full Company Profile

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD Financial Statements

News

Mike Ashley’s Frasers buys £3m stake in Marks Electrical

In a stock market filing, Marks revealed that Frasers has bought 6.73 million shares in the business.

10 months ago - Evening Standard

Three Quick Facts: AstraZeneca, Marks Electrical, BAE Systems

Buoyant demand sustains revenue growth at AstraZeneca, solid revenue growth at Marks Electrical, BAE Systems on track following upgrades

10 months ago - The Armchair Trader